Treatment of acute lymphoblastic leukemia.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D001215:Asparaginase / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000517:prevention & control; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003588:Cytopathogenic Effect, Viral; D003630:Daunorubicin / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D007942:Leukemia, Experimental / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D008578:Meninges; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D009858:Oncogenic Viruses / Q000472:pathogenicity; D010348:Patient Care Team; D012328:RNA Viruses / Q000201:enzymology; D012194:RNA-Directed DNA Polymerase / Q000378:metabolism; D012075:Remission, Spontaneous; D018894:Reverse Transcriptase Inhibitors; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D018894:Reverse Transcriptase Inhibitors; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D000324:Adrenocorticotropic Hormone; D015122:Mercaptopurine; D012194:RNA-Directed DNA Polymerase; D001215:Asparaginase; D008727:Methotrexate; D003630:Daunorubicin